Ahlan Bikom Ya fellow investors. We began coverage on GALT back in May of 2018 and been very accurate in out theses. Here's a couple of our first articles.

[https://msmoneymoves.com/august-2/]

[https://msmoneymoves.com/2018/10/02/galectin-blocker-is-front-runner-in-fight-against-nash-cirrhosis/]

[https://msmoneymoves.com/2018/09/20/market-not-grasping-the-magnitude-of-galt-phase1b-keytruda-combo-study/]

and if you like what you read you can subscribe to our free newsletter at

[https://msmoneymoves.com/contact/]

Shukran jami3
Sultan
MS Money Moves
sfbeard@ucdavis.edu
559-381-5250